Clinical trials / NCT07449702
NCT07449702Phase 2Recruiting

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Study sponsor: Oruka Therapeutics, Inc. · ORKA

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2030-05Estimated
Enrollment · participants240Estimated
Source updated2026-09-23Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs)

+ After

Measure: Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs)

Planned enrollment increased by 160 participants

− Before

80 participants (planned)

+ After

240 participants (planned)

Primary completion date changed

− Before

Nov 2028

+ After

May 2030

Check registry source